Sarepta's EMBARK study confirms Elevidys offers sustained Duchenne treatment benefits, including motor function improvement ...
The FDA has accepted Merck's (MRK) supplemental NDA with priority review for its drug Welireg for the treatment of a rare ...
Sarepta (SRPT) announced topline results from Part 2 of EMBARK, a global, randomized, double-blind, placebo-controlled, Phase 3 clinical study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback